MARK HERMAN to Liver
This is a "connection" page, showing publications MARK HERMAN has written about Liver.
Connection Strength
1.931
-
A Systems Approach Dissociates Fructose-Induced Liver Triglyceride from Hypertriglyceridemia and Hyperinsulinemia in Male Mice. Nutrients. 2021 Oct 18; 13(10).
Score: 0.454
-
Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets. J Biol Chem. 2021 Jan-Jun; 296:100623.
Score: 0.437
-
Intestinal, but not hepatic, ChREBP is required for fructose tolerance. JCI Insight. 2017 12 21; 2(24).
Score: 0.348
-
Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice. J Biol Chem. 2022 10; 298(10):102401.
Score: 0.120
-
Molecular aspects of fructose metabolism and metabolic disease. Cell Metab. 2021 12 07; 33(12):2329-2354.
Score: 0.113
-
Metabolic liver disease - what's in a name? Nat Rev Endocrinol. 2021 02; 17(2):79-80.
Score: 0.108
-
Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes. Curr Diab Rep. 2019 08 03; 19(9):77.
Score: 0.097
-
Fructose metabolism and metabolic disease. J Clin Invest. 2018 02 01; 128(2):545-555.
Score: 0.088
-
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol Metab. 2017 01; 6(1):14-21.
Score: 0.081
-
Integration of metabolomic and transcriptomic analyses reveals regulatory functions of the ChREBP transcription factor in energy metabolism. Cell Rep. 2025 Feb 25; 44(2):115278.
Score: 0.036
-
Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street. Mol Metab. 2021 10; 52:101261.
Score: 0.028
-
The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans. Mol Metab. 2017 11; 6(11):1493-1502.
Score: 0.021